Razuprotafib (AKB-9778) is a novel small molecule Tie2 activator being developed in phase 2 clnical trials by Aerpio company for a number of indications including Diabetic Nephropathy, Open Angle Glaucoma and ARDS due to COVID-19. It enhances endothelial function and stabilizes blood vessels, including pulmonary and renal vasculature. Razuprotafib restores Tie2 activation to stabilize the vasculature providing breakthrough potential for reducing the severity of COVID-19 associated pulmonary and vascular pathology resulting in fewer patients requiring ventilator support, decreased time in ICU on ventilator support and more rapid and complete recovery with concomitant reduction mortality. Additionally, razuprotafib together with emerging antiviral drugs could provide the optimal combination of host and virus targeted therapy for prevention and treatment of COVID-19 and COVID-19 related ARDS. Razuprotafib is also a protein tyrosine phosphatase ss (HPTPss) inhibitor.

纯度：≥98%

CAS：1008510-37-9